MedPath

Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Public
Established
2001-01-01
Employees
51
Market Cap
-
Website
http://www.infi.com

Clinical Trials

53

Active:32
Completed:14

Trial Phases

4 Phases

Phase 1:31
Phase 2:10
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials

Phase 1
31 (72.1%)
Phase 2
10 (23.3%)
Not Applicable
1 (2.3%)
Phase 3
1 (2.3%)

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Phase 2
Completed
Conditions
Advanced Cancer
Bladder Cancer
Urothelial Carcinoma
Solid Tumor
Interventions
First Posted Date
2019-06-10
Last Posted Date
2022-11-25
Lead Sponsor
Infinity Pharmaceuticals, Inc.
Target Recruit Count
49
Registration Number
NCT03980041
Locations
🇺🇸

Parkview Physicians, Fort Wayne, Indiana, United States

🇺🇸

University of MD - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

Karmanos Cancer Center, Detroit, Michigan, United States

and more 26 locations

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Phase 2
Active, not recruiting
Conditions
Breast Cancer
Renal Cell Carcinoma
Interventions
First Posted Date
2019-05-23
Last Posted Date
2023-08-14
Lead Sponsor
Infinity Pharmaceuticals, Inc.
Target Recruit Count
91
Registration Number
NCT03961698
Locations
🇺🇸

Ironwood Cancer and Research Center, Chandler, Arizona, United States

🇺🇸

Arizona Oncology Associates, Tucson, Arizona, United States

🇺🇸

Arizona Clinical Research Center, Tucson, Arizona, United States

and more 21 locations

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Phase 1
Conditions
Advanced Solid Tumors (Part A/B/C/D)
Triple Negative Breast Cancer (Part F)
Adrenocortical Carcinoma (Part G)
Non-small Cell Lung Cancer (Part E)
Mesothelioma (Part G)
High-circulating Myeloid-derived Suppressor Cells (Part H)
Melanoma (Part E)
Squamous Cell Cancer of the Head and Neck (Part E)
Interventions
First Posted Date
2015-12-22
Last Posted Date
2022-04-04
Lead Sponsor
Infinity Pharmaceuticals, Inc.
Target Recruit Count
219
Registration Number
NCT02637531
Locations
🇺🇸

UCSD, San Diego, California, United States

🇺🇸

UCLA, Santa Monica, California, United States

🇺🇸

Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States

and more 8 locations

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Not Applicable
Completed
Conditions
Basal Cell Carcinoma
Chondrosarcoma
Interventions
First Posted Date
2012-05-31
Last Posted Date
2012-11-14
Lead Sponsor
Infinity Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT01609179
Locations
🇺🇸

University of Colorado Denver, Aurora, Colorado, United States

🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

Phase 1
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2011-09-02
Last Posted Date
2014-11-13
Lead Sponsor
Infinity Pharmaceuticals, Inc.
Target Recruit Count
47
Registration Number
NCT01427946
Locations
🇺🇸

University of Colorado Denver, Aurora, Colorado, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.